Protecting the heart during chemotherapy for children with leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to assess the effectiveness of cardioprotective medications, specifically ACE inhibitors and β-blockers, in reducing chemotherapy-induced cardiotoxicity in pediatric patients diagnosed with acute leukemia. The study will measure the impact of these medications on the left ventricular ejection fraction (LVEF) using 2D echocardiography at the beginning and end of the 42-day induction phase of chemotherapy. By comparing the cardiotoxicity profiles of the two medication groups, the study seeks to identify the most effective cardioprotective strategy for young patients undergoing chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
* Ability to take oral medication.
* Age 2-18 years at the time of diagnosis.

Exclusion Criteria:

* Documented allergy to cardioprotective medications

Where it's running

• Faculty of Pharmacy, Ain Shams University
  Cairo, Egypt Recruiting
• Faculty of Pharmacy, Ain Shams University
  Cairo, Egypt Recruiting

Study contacts

• Principal investigator: Manal Hamed El-Hamamsy, Prof — Ain Shams University
• Study coordinator: Christen Said
• Email: keristin.nazir21@pharma.asu.edu.eg
• Phone: +201093942389

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Pharmacogenomic panel to predict chemotherapy- and immunotherapy-induced heart damage

  A pharmacogenomic and pharmacoepigenetic panel is being tested to see if it can predict which breast cancer patients will develop heart damage from chemotherapy or immunotherapy.

  Recruiting Beneficência Portuguesa de São Paulo · Fortaleza, Ceará and 5 other locations · NCT07663357

• Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

  This study tests whether heart changes seen on ultrasound and blood biomarkers can detect early heart problems in women receiving standard chemotherapy and anti-HER2 therapy for early breast cancer.

  Recruiting Gazi University · Ankara, Ankara · NCT07588425

• Serial contrast cardiac MRI and biomarker testing to detect anthracycline-related heart damage

  This study tries to see if repeated contrast cardiac MRI plus blood, urine, and stool biomarker checks can find early heart damage in people getting anthracycline chemotherapy.

  Recruiting Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Stuttgart · NCT07528586

• Early detection of heart and blood vessel damage from cancer treatments in children and young adults

  This project tests whether newer heart and vessel imaging and stiffness tests can find treatment-related damage earlier in children, adolescents, and young adult cancer patients.

  Recruiting at 5 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 4 other locations · NCT07382141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.